MALVERN, Pa.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced that new preclinical data on its Smac mimetic drug candidate birinapant (formerly TL32711) were presented this week at the 103rd American Association for Cancer Research (AACR) Annual Meeting in Chicago. Birinapant has entered Phase 2 clinical trials for several solid tumors and a Phase 1/2 study in acute myeloid leukemia (AML) is ongoing.
